[PDF] Top 20 Herramientas colaborativas para la enseñanza de asignaturas técnicas
Has 10000 "Herramientas colaborativas para la enseñanza de asignaturas técnicas" found on our website. Below are the top 20 most common "Herramientas colaborativas para la enseñanza de asignaturas técnicas".
Clinical use of crizotinib for the treatment of non-small cell lung cancer
... every clinical pathology labora- tory, ALK immunohistochemistry analysis could easily be incorporated into the normal staining performed during diag- nosis and histological subtyping of ...the small subset ... See full document
54
Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib
... personalized treatment based on genomic variations has significantly changed lung cancer clinical practice in the past 10 ...with non-small-cell lung cancer ... See full document
10
Development of Aseptic Renal Abscess in a Patient with Non Small Cell Lung Cancer with ALK Translocation during Crizotinib Treatment
... Background: Crizotinib is a tyrosine kinase inhibitor of ALK, MET and ...of Crizotinib with the development of renal cyst in patients with non-small-cell lung cancer ...of ... See full document
467
The role of brigatinib in crizotinib-resistant non-small cell lung cancer
... 270 advanced TKI-naïve, ALK-positive NSCLC patients with no more than one prior line of systemic treatment will be randomized (1:1) to receive brigatinib (1 week at 90 mg daily followed by 180 mg daily) or ... See full document
6
Afatinib for the treatment of metastatic non-small cell lung cancer
... inhibitor, crizotinib, are being used as first-line therapy for patients with advanced NSCLC who have activat- ing EGFR mutation and ALK rearrangements, ...their use as first-line therapies in select ... See full document
18
Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
... stem cell factor (SCF) is crucial for KIT activation since, only in the presence of SCF, the concomitant administration of crizotinib and imatinib induces a markedly decreased proliferation of cells ... See full document
31
<p>Brigatinib for <em>ALK</em>-positive metastatic non-small-cell lung cancer: design, development and place in therapy</p>
... Ba/F3 cell lines was generated containing native EML4-ALK or 17 different secondary ALK ...of crizotinib, ceritinib and alectinib, ...than crizotinib for all ...to treatment (IC 50 = 184 ... See full document
15
Novel ALK inhibitors in clinical use and development
... of treatment with an ALK ...of crizotinib resistance is the amplification of EML4-ALK fusion gene through two methods, more copies per cell and more cells displaying the rearrangement pattern ...of ... See full document
5
<p>Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the <em>KDR</em> Gene Polymorphism</p>
... million lung cancer-related deaths in ...the treatment of non-small cell lung cancer (NSCLC) in terms of molecular and targeted ...of cancer in precision ... See full document
15
Case Report HIP1-ALK fusion variant in non-small-cell lung cancer and response to crizotinib: a case report and review of the literature
... adjuvant crizotinib after complete surgical resection with no recurrence at the time of their report (15 ...months crizotinib treatment (PR) and then 12 months Alectinib treatment ...of ... See full document
46
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
... Colorado Cancer Center, Aurora ...Yonsei Cancer Center, Yonsei University College of Medicine ...National Cancer Center, Goyang ...and Treatment of Cancer, Meldola ...of Cancer ... See full document
12
Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
... a treatment option in metastatic non-small cell lung cancer, for which oncogenic drivers have been ...and non-squamous lung ...of lung cancer, quite ... See full document
6
Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
... of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%–5% of all NSCLC ...to ... See full document
22
Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report
... original crizotinib treatment and applied for three ...additional treatment procedures were conducted to prevent ILD, but the patient died 20 days after the first administration of ...a lung ... See full document
27
Crizotinib in non small cell lung cancer
... of treatment of locally advanced and metastatic non-small cells lung cancer ...new treatment options have been develop- ...activating cancer cells led to the iden- ... See full document
16
Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer
... chemotherapy, crizotinib, and local treatment by radio- therapy (RT); response to therapy; pattern of failure; time to progression (TTP); and survival outcome, were ... See full document
24
Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study
... advanced non-squamous non-small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (bev) or bev+pemetrexed (pem) after first-line (1L) ... See full document
41
Rational use of cetuximab in the treatment of advanced non-small cell lung cancer
... Abstract: Lung cancer is the leading cause of mortality in the United ...States. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung ...of ... See full document
7
Safety and Efficacy of Racotumomab Alum Vaccine as Second Line Therapy for Advanced Non Small Cell Lung Cancer
... vaccinated cancer patients ...I clinical trials that included patients with melanoma, breast cancer and lung cancer (small and non-small cell lung ... See full document
6
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
... the treatment with erlotinib compared to BSC or chemo- therapy [12-22]: One study focused on first-line treat- ment [16], three on first-line maintenance treatment [13-15] and seven studies on subsequent ... See full document
7
Related subjects